Objective

S100A9 is a calcium- and zinc-binding molecule of S100 family. The aim of the study was to evaluate the role of S100A9 in osteosarcoma (OS) and its value as a diagnostic and therapeutic target in OS. Methods: Quantitative real-time polymerase chain reaction (qRT-PCR), immunohistochemistry and microdissection-based mRNA analysis were used to detect S100A9 mRNA and protein expression in OS and normal bone tissues and its potential as a diagnostic marker in OS. In vitro experiments with RNA interference were performed to evaluate the functional role of S100A9 and its potential as a therapeutic target in OS. Results: S100A9 mRNA levels were significantly higher in OS tissues than that of in normal bone tissues. Receiver operating characteristic curves showed that S100A9 could be a useful diagnostic marker in OS. In vitro data showed that inhibition of S100A9 decreased the proliferation and invasiveness of OS cells, and these findings were supported by microarray data. Conclusions: Assessment of S100A9 mRNA expression is a promising tool for the diagnosis of OS, and S100A9 may be a promising therapeutic target in OS.

中文翻译：

---

S100A9在骨肉瘤发展中以及作为诊断标志物和治疗靶标的临床重要性。

目的

S100A9是S100家族的钙和锌结合分子。该研究的目的是评估S100A9在骨肉瘤（OS）中的作用及其在OS中作为诊断和治疗靶标的价值。方法：采用定量实时聚合酶链反应（qRT-PCR），免疫组织化学和显微解剖技术进行mRNA分析，以检测OS和正常骨组织中S100A9 mRNA和蛋白的表达及其在OS中作为诊断标志物的潜力。进行了具有RNA干扰的体外实验，以评估S100A9的功能作用及其在OS中作为治疗靶标的潜力。结果：OS组织中的S100A9 mRNA水平显着高于正常骨组织。接收器工作特性曲线表明，S100A9可能是OS中有用的诊断标记。体外数据显示，对S100A9的抑制作用会降低OS细胞的增殖和侵袭性，这些发现得到了微阵列数据的支持。结论：评估S100A9 mRNA表达是诊断OS的有前途的工具，S100A9可能是OS的有前途的治疗靶点。